NZ573719A - Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis - Google Patents

Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis

Info

Publication number
NZ573719A
NZ573719A NZ573719A NZ57371907A NZ573719A NZ 573719 A NZ573719 A NZ 573719A NZ 573719 A NZ573719 A NZ 573719A NZ 57371907 A NZ57371907 A NZ 57371907A NZ 573719 A NZ573719 A NZ 573719A
Authority
NZ
New Zealand
Prior art keywords
epa
polar
culture
biomass
side chain
Prior art date
Application number
NZ573719A
Other languages
English (en)
Inventor
Karl Thomas Geiringer
Hywel David Griffiths
Original Assignee
Photonz Corp Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photonz Corp Ltd filed Critical Photonz Corp Ltd
Priority to NZ573719A priority Critical patent/NZ573719A/en
Publication of NZ573719A publication Critical patent/NZ573719A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6409—Fatty acids
    • C12P7/6427—Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone
    • C12P7/6432—Eicosapentaenoic acids [EPA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6458—Glycerides by transesterification, e.g. interesterification, ester interchange, alcoholysis or acidolysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
NZ573719A 2006-07-05 2007-07-05 Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis NZ573719A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ573719A NZ573719A (en) 2006-07-05 2007-07-05 Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NZ54833906 2006-07-05
PCT/NZ2007/000172 WO2008004900A1 (en) 2006-07-05 2007-07-05 Production of ultrapure epa and polar lipids from largely heterotrophic culture
NZ573719A NZ573719A (en) 2006-07-05 2007-07-05 Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis

Publications (1)

Publication Number Publication Date
NZ573719A true NZ573719A (en) 2011-08-26

Family

ID=38894787

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ573719A NZ573719A (en) 2006-07-05 2007-07-05 Production of ultrapure eicosapentaenoic acid and polar lipids from largely heterotrophic culture of nitzschia laevis

Country Status (8)

Country Link
US (3) US8877465B2 (https=)
EP (1) EP2044208A4 (https=)
JP (1) JP5658876B2 (https=)
AU (1) AU2007270135B9 (https=)
CA (1) CA2656311C (https=)
NO (1) NO20090531L (https=)
NZ (1) NZ573719A (https=)
WO (1) WO2008004900A1 (https=)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2397655C (en) 2000-01-19 2012-06-05 Craig M. Ruecker Solventless extraction process
US8343753B2 (en) 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2334295B1 (en) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
SI2395991T1 (sl) 2009-02-10 2013-12-31 Amarin Pharmaceuticals Ireland Limited Uporaba etil estra eikozapentaenojske kisline za zdravljenje hipertrigliceridemije
SG10201605794PA (en) 2009-04-29 2016-09-29 Amarin Pharmaceuticals Ie Ltd Stable Pharmaceutical Composition And Methods Of Using Same
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP3318255B1 (en) * 2009-06-15 2021-03-10 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating stroke in a subject on concomitant statin therapy
US8399226B2 (en) 2009-06-16 2013-03-19 E I Du Pont De Nemours And Company High eicosapentaenoic acid oils from improved optimized strains of Yarrowia lipolytica
CN101613724B (zh) * 2009-07-28 2011-04-06 嘉吉烯王生物工程(湖北)有限公司 重复利用高山被孢霉菌粕制备花生四烯酸的方法
ES2732493T3 (es) * 2009-09-18 2019-11-22 Phycoil Biotechnology Int Inc Fermentación de microalgas usando iluminación controlada
AU2010298222B2 (en) 2009-09-23 2017-01-05 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
EP2519332B1 (en) * 2009-12-30 2014-03-05 BASF Pharma (Callanish) Limited Simulated moving bed chromatographic separation process for the purification of polyunsaturated fatty acids
AU2013204090B2 (en) * 2009-12-30 2015-01-29 Basf Pharma (Callanish) Limited Simulated moving bed chromatographic separation process
US9924733B2 (en) 2010-01-19 2018-03-27 Dsm Ip Assets B.V. Eicosapentaenoic acid-producing microorganisms, fatty acid compositions, and methods of making and uses thereof
WO2011109724A1 (en) * 2010-03-04 2011-09-09 Amarin Pharma, Inc. Compositions and methods for treating and/or preventing cardiovascular disease
EP2576801B1 (en) 2010-06-01 2019-10-02 DSM IP Assets B.V. Extraction of lipid from cells and products therefrom
JP5678180B2 (ja) * 2010-06-09 2015-02-25 フォトンズ コーポレーション リミテッド 高度精製に適した、エイコサペンタエン酸を含む組成物
FR2964667B1 (fr) * 2010-09-15 2014-08-22 Fermentalg Procede de culture d'algues unicellulaires mixotrophes en presence d'un apport lumineux discontinu sous forme de flashs
US20130309719A1 (en) * 2010-10-06 2013-11-21 Photonz Corporation Limited Heterotrophic microbial production of xanthophyll pigments
US10479969B2 (en) 2010-10-11 2019-11-19 Phycoil Biotechnology International. Inc. Utilization of wastewater for microalgal cultivation
NZ744990A (en) * 2010-11-29 2019-10-25 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
CN103327982A (zh) * 2011-02-01 2013-09-25 日本水产株式会社 性功能改善剂
WO2012103685A1 (en) * 2011-02-01 2012-08-09 Nippon Suisan Kaisha, Ltd. Sexual function improving agent
EP2673371A1 (en) * 2011-02-11 2013-12-18 E.I. Du Pont De Nemours And Company An eicosapentaenoic acid concentrate
GB201111595D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Improved process
GB201111594D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New improved process
GB201111591D0 (en) 2011-07-06 2011-08-24 Equateq Ltd Further new process
GB201111589D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New modified process
GB201111601D0 (en) 2011-07-06 2011-08-24 Equateq Ltd New process
AU2012285806B2 (en) * 2011-07-21 2017-09-14 Dsm Ip Assets B.V. Fatty acid compositions
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
ES2891473T3 (es) 2012-01-06 2022-01-28 Amarin Pharmaceuticals Ie Ltd Composiciones y métodos para reducir los niveles de alta sensibilidad (hs-CRP) en un sujeto
FR2988098A1 (fr) * 2012-03-16 2013-09-20 Fermentalg Production d'acide docosahexaenoique en mode mixotrophe par nitzschia
US9719115B2 (en) * 2012-05-10 2017-08-01 Kyoto University Method for producing oxo fatty acid and rare fatty acid
WO2013192109A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use
NZ727849A (en) 2012-06-29 2018-06-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
WO2014074552A2 (en) 2012-11-06 2014-05-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
WO2014074772A1 (en) 2012-11-09 2014-05-15 Heliae Development, Llc Mixotrophic, phototrophic, and heterotrophic combination methods and systems
WO2014074770A2 (en) 2012-11-09 2014-05-15 Heliae Development, Llc Balanced mixotrophy methods
AU2013354979A1 (en) * 2012-12-06 2015-06-11 Matinas Biopharma, Inc. Administering compositions comprising docosapentaenoic acid
US9629820B2 (en) 2012-12-24 2017-04-25 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
AU2013371074B2 (en) * 2012-12-24 2018-07-26 Qualitas Health Inc. Eicosapentaenoic acid (EPA) formulations
US10123986B2 (en) 2012-12-24 2018-11-13 Qualitas Health, Ltd. Eicosapentaenoic acid (EPA) formulations
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
GB201300354D0 (en) 2013-01-09 2013-02-20 Basf Pharma Callanish Ltd Multi-step separation process
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140275483A1 (en) * 2013-03-15 2014-09-18 Aurora Algae, Inc. Algal oil compositions
WO2014146098A1 (en) * 2013-03-15 2014-09-18 Aurora Algae, Inc. Compositions of crude algal oil
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US9428711B2 (en) 2013-05-07 2016-08-30 Groupe Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US8802880B1 (en) 2013-05-07 2014-08-12 Group Novasep Chromatographic process for the production of highly purified polyunsaturated fatty acids
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
JP6563393B2 (ja) 2013-08-01 2019-08-21 フェルマンタル 珪藻バイオマスの生産方法
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
NL2011472C2 (en) * 2013-09-19 2015-03-23 Univ Delft Tech Storage compound production by phototrophic diatoms.
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3118186B1 (fr) 2013-12-11 2022-02-09 Novasep Process Installation chromatographique de production d acides gras polyinsatures
AU2014369040B2 (en) 2013-12-20 2019-12-05 Dsm Ip Assets B.V. Processes for obtaining microbial oil from microbial cells
PL3083546T3 (pl) 2013-12-20 2022-05-16 Dsm Ip Assets B.V. Sposoby wytwarzania oleju mikrobiologicznego z komórek mikrobiologicznych
AR098895A1 (es) 2013-12-20 2016-06-22 Dsm Ip Assets Bv Proceso para obtener aceite microbiano a partir de células microbianas
NZ721413A (en) 2013-12-20 2022-05-27 Dsm Ip Assets Bv Processes for obtaining microbial oil from microbial cells
CN105939710B (zh) 2013-12-20 2020-05-08 帝斯曼知识产权资产管理有限公司 用于从微生物细胞获得微生物油的方法
BR112016015718B1 (pt) 2014-01-07 2021-12-07 Novasep Process Solutions Processo de purificação de aminoácidos aromáticos
JP2015146788A (ja) * 2014-02-07 2015-08-20 三菱マテリアル株式会社 藻類培養方法及び藻類培養装置
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN109312370B (zh) * 2016-06-08 2022-06-14 瑞典海藻制造公司 从由工业生物膜处理收获的底栖羽纹硅藻中提取的硅藻壳
CN105912054B (zh) * 2016-06-24 2018-11-20 国网山东省电力公司聊城供电公司 一种油色谱在线装置柜的温控系统及其工作方法与应用
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
CN107099379A (zh) * 2017-06-09 2017-08-29 云南中烟工业有限责任公司 一种用于电子烟的津巴布韦烟草净油
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
FR3085962B1 (fr) 2018-09-14 2021-06-18 Fermentalg Procede d'extracton d'une huile riche en pufa
LT3750536T (lt) 2018-09-24 2026-03-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos reiškinių rizikos subjekto organizme sumažinimo būdai
JP7395144B2 (ja) * 2019-04-05 2023-12-11 三菱重工機械システム株式会社 微細藻培養方法および微細藻培養装置
BR112022009189A2 (pt) 2019-11-12 2022-07-26 Amarin Pharmaceuticals Ie Ltd Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
WO2021211990A1 (en) * 2020-04-17 2021-10-21 Wake Forest University Lipid compositions and methods of preparation thereof
GB202016236D0 (en) * 2020-10-13 2020-11-25 Givaudan Sa Composition
AU2022263358A1 (en) 2021-04-21 2023-11-30 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1969433U (de) * 1967-04-14 1967-09-28 Bernhard Dipl Ing Winkler Beschilderungselement.
JPS5946225A (ja) * 1982-09-09 1984-03-15 Kogyo Kaihatsu Kenkyusho 抗動脈硬化剤の製造方法
JPS6163624A (ja) * 1984-09-05 1986-04-01 Nisshin Oil Mills Ltd:The エイコサペンタエン酸含量の高い糖脂質の製造法
JPH0297373A (ja) * 1988-09-30 1990-04-09 Koujiyouen:Kk ビールの製造方法
JPH0297393A (ja) 1988-10-03 1990-04-09 Sagami Chem Res Center エイコサペンタエン酸を含むリン脂質組成物の海洋微生物による製造法
JPH02145191A (ja) * 1988-11-29 1990-06-04 Tosoh Corp 海洋性微生物からの高度不飽和脂肪酸の分離方法
US5244921A (en) * 1990-03-21 1993-09-14 Martek Corporation Eicosapentaenoic acids and methods for their production
WO1994024984A2 (en) * 1993-04-30 1994-11-10 Winget Rodner R Anti-inflammatory compositions containing eicosapentaenoic acid bearing monogalactosyldiacylglycerol and methods relating thereto
GB9404483D0 (en) 1994-03-08 1994-04-20 Norsk Hydro As Refining marine oil compositions
DE19629433A1 (de) 1996-07-22 1998-01-29 Hoechst Ag Omega-3-fettsäurenenthaltende Zubereitung aus Mikroorganismen als Prophylaktikum bzw. Therapeutikum gegen parasitäre Erkrankungen beim Tier
JP3836231B2 (ja) * 1997-10-17 2006-10-25 日本化学飼料株式会社 ホタテガイ中腸腺から得られる高度不飽和脂肪酸含有油及びその製造方法
AU2004235641B2 (en) * 1999-01-27 2006-09-14 Amarin Neuroscience Limited Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
CA2273570A1 (en) * 1999-05-31 2000-11-30 Jfs Envirohealth Ltd. Concentration and purification of polyunsaturated fatty acid esters by distillation-enzymatic transesterification coupling
JP4170542B2 (ja) * 1999-11-18 2008-10-22 日油株式会社 高度不飽和脂肪酸誘導体の製造方法及び高純度エイコサペンタエン酸誘導体
CA2397655C (en) * 2000-01-19 2012-06-05 Craig M. Ruecker Solventless extraction process
EP1392623A4 (en) * 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS
EP1549753B1 (en) * 2002-10-11 2010-09-08 Nippon Suisan Kaisha, Ltd. Process for producing microbial fat or oil having lowered unsaponifiable matter content
GB0301701D0 (en) 2003-01-24 2003-02-26 Ensay Ltd Psoriasis and Eicosapentaenoic acid
US8557551B2 (en) * 2004-09-10 2013-10-15 Dsm Ip Assets B.V. Compositions and methods for making and modifying oils
JP5491697B2 (ja) * 2004-10-15 2014-05-14 フォトンズ コーポレイション リミテッド 高レベルオメガ−３および低レベル飽和脂肪酸を含む組成物
US20070225370A1 (en) * 2006-03-21 2007-09-27 Joar Opheim Nutritional Compositions and Methods

Also Published As

Publication number Publication date
EP2044208A4 (en) 2012-02-22
US20150057353A1 (en) 2015-02-26
JP5658876B2 (ja) 2015-01-28
US20170326090A1 (en) 2017-11-16
EP2044208A1 (en) 2009-04-08
CA2656311C (en) 2016-06-21
JP2009542205A (ja) 2009-12-03
NO20090531L (no) 2009-02-03
AU2007270135B2 (en) 2013-06-20
US20100069492A1 (en) 2010-03-18
US8877465B2 (en) 2014-11-04
CA2656311A1 (en) 2008-01-10
AU2007270135A1 (en) 2008-01-10
AU2007270135B9 (en) 2013-06-27
WO2008004900A1 (en) 2008-01-10

Similar Documents

Publication Publication Date Title
CA2656311C (en) Ultra pure epa and polar lipids produced in largely heterotrophic culture
Bajpai et al. Eicosapentaenoic acid (EPA) production from microorganisms: a review
US7767427B2 (en) Production method of oil or fat containing polyunsaturated fatty acid-containing triglyceride
KR101175773B1 (ko) 불비누화 물질 함량을 저감시킨 미생물 유지의 제조 방법및 그 유지
JP4522257B2 (ja) エステル交換油脂またはトリグリセリドの製造方法
US10844346B2 (en) Compositions comprising eicosapentaenoic acid suitable for high purification
CN105925627A (zh) 微生物油及其制备方法
JP4283351B2 (ja) 新規な油脂組成物の製造方法および用途
JPH0913075A (ja) 血中脂質を低減する油脂
CN112618723A (zh) 一种结构化磷脂及其制备方法和应用
KR20070122059A (ko) 인지질 조성물 및 인지질 조성물 제조방법
Haraldsson et al. PUFA production from marine sources for use in food
EP2079824A2 (en) Modified alkoxyglycerols

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
ERR Error or correction

Free format text: THE INVENTOR HAS BEEN CORRECTED TO 1243161, GRIFFITHS, HYWEL DAVID; 1329642, GEIRINGER, KARL THOMAS, 81 CHAMBERLAIN ROAD, KARORI, WELLINGTON 6012, NZ

Effective date: 20130620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 05 JUL 2017 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20140610

ASS Change of ownership

Owner name: FERMENTALG, FR

Effective date: 20171114

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUL 2018 BY ACUMASS

Effective date: 20171215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUL 2019 BY ACUMASS

Effective date: 20180626

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUL 2020 BY ACUMASS

Effective date: 20190619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUL 2021 BY ACUMASS

Effective date: 20200618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUL 2022 BY ACUMASS

Effective date: 20210618

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUL 2023 BY ACUMASS

Effective date: 20220620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUL 2024 BY ACUMASS

Effective date: 20230621

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUL 2025 BY ACUMASS

Effective date: 20240619

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 05 JUL 2026 BY ACUMASS

Effective date: 20250623